These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34021591)

  • 1. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
    Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
    Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
    Bersanelli M; Giannarelli D; De Giorgi U; Pignata S; Di Maio M; Clemente A; Verzoni E; Giusti R; Di Napoli M; Aprile G; Ermacora P; Catino A; Scotti V; Mazzoni F; Guglielmini PF; Veccia A; Maruzzo M; Rossi E; Grossi F; Casadei C; Ficorella C; Montesarchio V; Verderame F; Rizzo M; Guaitoli G; Fratino L; Accettura C; Mencoboni M; Zustovich F; Baldessari C; Cinieri S; Camerini A; Laera L; Sorarù M; Zucali PA; Guadalupi V; Leonardi F; Tiseo M; Tognetto M; Di Costanzo F; Pinto C; Negrini G; Russo A; Migliorino MR; Filetti M; Buti S;
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Tsiakos K; Kyriakoulis KG; Kollias A; Kyriakoulis IG; Poulakou G; Syrigos K
    J Immunother; 2022 Jul-Aug 01; 45(6):291-298. PubMed ID: 35639000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
    Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
    Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study.
    Nakashima K; Homma Y; Taniguchi J; Kubota N; Otsuki A; Ito H; Otsuka Y; Kondo K; Ohfuji S; Fukushima W; Hirota Y
    J Infect Chemother; 2023 Nov; 29(11):1038-1045. PubMed ID: 37481070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
    Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Keam B; Kang CK; Jun KI; Moon SM; Suh KJ; Lee DW; Ock CY; Kim M; Choi Y; Lim Y; Lee KH; Kim SH; Kim TM; Kim TY; Oh DY; Kim DW; Im SA; Lee JS; Kim ES; Kim HB; Kim NJ; Kim YJ; Park WB; Oh MD
    Clin Infect Dis; 2020 Jul; 71(2):422-425. PubMed ID: 31680143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
    Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
    Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors.
    Gwynn ME; DeRemer DL; Saunders KM; Parikh J; Bollag RJ; Clemmons AB
    J Oncol Pharm Pract; 2020 Apr; 26(3):647-654. PubMed ID: 31474214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
    Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
    Yang Y; Xu G
    Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients.
    Bersanelli M; Scala S; Affanni P; Veronesi L; Colucci ME; Banna GL; Cortellini A; Liotta F
    Immunotherapy; 2020 Feb; 12(2):105-110. PubMed ID: 32046555
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
    Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
    Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Grima AA; Kwong JC; Richard L; Reid J; Raphael J; Basta NE; Carignan A; Top KA; Brousseau N; Blanchette PS; Sundaram ME;
    Vaccine; 2024 Mar; 42(7):1498-1505. PubMed ID: 38341288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature.
    Desage AL; Bouleftour W; Rivoirard R; Magne N; Collard O; Fournel P; Tissot C
    Am J Clin Oncol; 2021 Mar; 44(3):109-113. PubMed ID: 33350679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
    Hibino M; Uryu K; Takeda T; Kunimatsu Y; Shiotsu S; Uchino J; Hirai S; Yamada T; Okada A; Hasegawa Y; Hiranuma O; Chihara Y; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T; Takayama K
    J Thorac Oncol; 2022 Aug; 17(8):1002-1013. PubMed ID: 35752437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors.
    Kang CK; Kim HR; Song KH; Keam B; Choi SJ; Choe PG; Kim ES; Kim NJ; Kim YJ; Park WB; Kim HB; Oh MD
    J Infect Dis; 2020 Nov; 222(11):1902-1909. PubMed ID: 32479600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.